This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Time to Get Personal With Insurers

This column was originally published on RealMoney on March 27 at 3:34 p.m. EST. It's being republished as a bonus for readers.

I favor financial companies with strong balance sheets and high business quality. Over a full market cycle, they will usually outperform the average lower-quality company.

There is an exception, though: When credit spreads are abnormally high (as from October 2002 to January 2004), and the credit cycle turns, it pays to buy low-quality companies that have survived the crisis. This would be one of the few times I would be tempted to lever up and buy all the momentum I can.

Simple screening techniques aren't generally applicable to financials, for the reasons that I outlined last week in the first part of this two-part series. Two relatively similar institutions may write business with decidedly different risk profiles. The one writing the more risky business will typically trade at lower price-to-earnings (P/E) and price-to-book (P/B) ratios, though free cash flow, could it be fairly measured, might show the company writing the higher quality business to be the cheaper one. Also, earnings quality will be higher for the company writing better-quality business and the likelihood of negative surprises will be lower.

I use screens as a starting point. Typically, I use a metric that compares P/B to prospective return on equity (for more on my screening methods click here ). This works best when comparing companies in very similar industries. I have nine models like this screening the subsectors of the U.S.-traded insurance universe.

That gives me a reasonable idea of what is rich and cheap. Then the hard step comes: overlaying the simple metric with knowledge of the quality of business written by the companies in question. Sometimes it leads me to buy companies that are technically rich and sell short companies that are technically cheap, because the value of quality business practices often outweighs apparent cheapness.

Let me give you an example from one of my subsectors, personal lines insurers. I set a market-cap limit of $200 million when I defined my group.

Personal lines insurers are facing pricing deterioration, but not as sharp as that of commercial lines insurers. Pure premium rates are falling in the low single digits, on average, but that varies from state to state. There are two relatively large companies leading the wave of price-cutting: St. Paul Travelers (STA) and Geico. Competitors allege that both are underwriting at an expected loss.

Competition is even sharper among the companies that underwrite "nonstandard" risks, i.e., bad driving record, no driving record, etc. The premiums are higher and many companies think that they have a better marketing/pricing model than the competition. Companies writing nonstandard business usually trade at a discount to those that write standard risks.

The ability to trust the published financials is relatively high in the personal lines space because of the "short-tailed" nature of the liabilities. When people suffer losses, they know and report them quickly, usually.

Given that backdrop, consider this graph of P/B to prospective ROE for 19 companies in the personal lines sector:

Gauging Valuations
Graphing price-to-book vs. ROE for the companies in the personal lines sector gives a sense of relative valuations
Source: David Merkel

The line going through the center of the dots is the "best fit" or "regression" line. Companies below the line may have P/B ratios too low for their ROEs, meaning that they are seemingly cheap; companies above the line may be overvalued. That gives me a starting point for analysis.

The regression line also can be used to predict price-to-book value ratios going forward. If the companies earn what analysts expect them to earn, we can project what the proper price-to-book value for the company should be relative to where other companies in the same industry trade. From that, it is simple to calculate the expected percentage price increase/decrease from the projected P/B ratio. Big caveat: The regression makes the assumption that earnings growth, required return and dividend policy will remain constant. This simplifying assumption must be tested qualitatively when analyzing companies.

Now consider this table of values from the regression:

Personal Property and Casualty Insurers
Symbol Name Market Cap P/E P/E (next year) Est. ROE P/B Est. P/B Possible Gain/Loss
AFFM Affirmative $197.3M 8.67 7.72 13% 1.03 1.37 33%
ALFA Alfa 1.338B 13.74 12.97 14 1.79 1.68 -6
ALL Allstate 35.184B 20.73 8.94 20 1.75 2.45 40
BRW Bristol West 571.7M 11.02 11.65 15 1.69 1.59 -6
CGI Commerce Group 1.796B 7.34 10.11 13 1.36 1.71 26
DRCT Direct General 346.8M 9.41 8.32 18 1.47 1.66 13
ERIE Erie Indemnity 3.196B 15.86 14.57 17 2.53 1.98 -22
FAC First Acceptance 588.3M 24.65 N/A 10 2.53 1.39 -45
HMN Horace Mann Educator 795.7M 11.10 10.84 13 1.36 1.55 14
IPCC Infinity Property and Casualty 871.5M 8.21 12.73 11 1.38 1.48 7
KFS Kingsway Financial 1.126B 8.11 8.35 18 1.50 1.82 21
MCY Mercury General 3.000B 11.90 12.16 15 1.87 1.88 1
MLAN Midland 650.6M 10.40 11.29 12 1.37 1.50 9
PGR Progressive 21.115B 15.22 15.68 22 3.43 2.48 -28
SAFC Safeco 6.520B 9.79 10.23 16 1.59 2.01 26
SAFT Safety Insurance 729.2M 7.66 10.75 17 1.86 1.76 -6
STFC State Auto Financial 1.372B 10.91 10.32 17 1.77 1.84 4
THG Hanover Insurance 2.803B N/A 12.52 12 1.44 1.69 17
TW 21st Century Insurance 1.376B 15.79 16.04 10 1.66 1.53 -8
Source: David Merkel

Once I get to this point, I take a deeper look at the 20% in a sector that seem to be the most underpriced and the 20% that are seemingly the most overpriced. In personal lines, that boils down to the top and bottom four.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TW $123.00 -4.25%
AFFM $0.00 -28.57%
SAFC $0.00 33.33%
ALL $67.60 3.60%
CGI $9.84 -0.10%


Chart of I:DJI
DOW 17,639.18 -12.08 -0.07%
S&P 500 2,048.09 -3.03 -0.15%
NASDAQ 4,716.4350 -9.2040 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs